Skip to main content
. 2021 Sep 12;14(9):e244271. doi: 10.1136/bcr-2021-244271

Figure 5.

Figure 5

PET scan done after 2 months of erdafitinib treatment demonstrated no FDG-avid metastatic disease identified in body. PET, positron emission tomography; FDG, fluorodeoxyglucose.